Metformina + Pioglitazona Pentafarma (Metformin Hydrochloride, Pioglitazone)

Metformina + Pioglitona Pentafarma is used in the management of type 2 diabetes mellitus and related hyperglycaemic conditions.

• Type 2 diabetes mellitus: improves overall glycaemic control when monotherapy is insufficient.
• Elevated fasting plasma glucose: lowers fasting glucose levels.
• High HbA1c: reduces HbA1c percentages toward target values.
• Insulin resistance: enhances peripheral insulin sensitivity.
• Hyperglycaemia after meals: attenuates post‑prandial glucose excursions.

• Metformin reduces hepatic gluconeogenesis and increases peripheral glucose uptake by activating AMP‑activated protein kinase, while pioglitazone binds to peroxisome proliferator‑activated receptor‑γ (PPAR‑γ) receptors, promoting transcription of insulin‑sensitive genes and improving adipocyte function. The combined actions decrease hepatic glucose output and enhance insulin sensitivity in muscle and adipose tissue, resulting in better overall blood‑sugar regulation.

The combination may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Nausea: mild to moderate gastrointestinal discomfort.
• Diarrhoea: frequent loose stools, especially at treatment initiation.
• Weight gain: modest increase due to fluid retention or adipose tissue changes.
• Edema: peripheral swelling, often in the ankles.
• Headache: transient cranial discomfort.

Serious or Rare Side Effects

• Lactic acidosis: a rare but life‑threatening metabolic disturbance.
• Heart failure exacerbation: fluid overload leading to dyspnoea.
• Hepatotoxicity: elevated liver enzymes indicating liver injury.
• Bone fracture: increased risk of osteoporotic fractures.
• Bladder cancer: potential association with long‑term pioglitazone use.

Patients should be evaluated for specific risk factors before initiating therapy.

• Renal function: assess creatinine clearance and adjust if impaired.
• Hepatic function: monitor liver enzymes prior to and during treatment.
• Cardiac status: evaluate for existing heart failure before use.
• Pregnancy and lactation: avoid unless benefits outweigh potential risks.
• Concomitant medications: review for drugs that may affect glucose or renal function.
• Store at room temperature: keep in the original container, protect from moisture and heat.

Metformina + Pioglitona Pentafarma can interact with several medicines, requiring careful management.

Major Interactions (Avoid)

• Insulin or sulfonylureas: increased risk of severe hypoglycaemia.
• Cimetidine: may raise metformin plasma concentrations.
• Strong CYP2C8 inhibitors (e.g., gemfibrozil): elevate pioglitazone levels.

Moderate Interactions (Monitor Closely)

• Diuretics: may potentiate fluid retention and edema.
• ACE inhibitors or ARBs: monitor renal function and potassium.
• Contrast media: temporary suspension of metformin recommended to avoid renal complications.